Repligen (RGEN) News
NASDAQ: RGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
173.88+10.04 (+6.13%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
RGEN news summary
We found 3 recent headlines mentioning Repligen (RGEN): 1 in the past week and 2 in the past 30 days, most often from Nasdaq. RGEN is making an outsized move today, up 6.13% at $173.88, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Repligen Corp Completes Acquisition Of BioLife Solutions", was published by Nasdaq on Oct 7, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Repligen headlines
- Repligen Corp Completes Acquisition Of BioLife Solutions(RTTNews) - Repligen Corp. (RGEN), a life sciences company, announced that it has completed the previously announced acquisition of BioLife Solutions, Inc. (BLFS), a developer and supplier of cell…NasdaqREGN, RGEN
- NVS Gets Positive CHMP Opinion for Cosentyx for Another IndicationNVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.NasdaqNVS, RGEN, ANIK, IONS
- HALO Stock Rises 36% in a Month: Here's What You Should KnowHalozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.NasdaqHALO, JNJ, RGEN, ARGX